Compared to Estimates, Stryker (SYK) Q4 Earnings: A Look at Key Metrics

For the quarter ended December 2025, Stryker (SYK) reported revenue of $7.17 billion, up 11.4% over the same period last year. EPS came in at $4.47, compared to $4.01 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $7.13 billion, representing a surprise of +0.61%. The company delivered an EPS surprise of +1.71%, with the consensus EPS estimate being $4.40.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales by Geography- International: $1.73 billion compared to the $1.72 billion average estimate based on four analysts. The reported number represents a change of +10.7% year over year.Net Sales by Geography- United States: $5.44 billion compared to the $5.44 billion average estimate based on four analysts. The reported number represents a change of +11.7% year over year.Net Sales by Business- MedSurg and Neurotechnology: $4.56 billion versus $4.53 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +17.5% change.Net Sales by Geography- Orthopaedics: $2.61 billion compared to the $2.61 billion average estimate based on six analysts. The reported number represents a change of +2.2% year over year.Net Sales by Geography- Orthopaedics- Hips: $499 million versus $504.79 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +7.8% change.Net Sales by Geography- Orthopaedics- Other: $267 million versus $253.33 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +20.3% change.Net Sales by Geography- Orthopaedics- Trauma and Extremities: $1.09 billion versus $1.1 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +9% change.Net Sales by Business- MedSurg and Neurotechnology- Instruments: $925 million compared to the $876.94 million average estimate based on five analysts. The reported number represents a change of +17.1% year over year.Net Sales by Business- MedSurg and Neurotechnology- Endoscopy: $1.15 billion versus $1.1 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +13.8% change.Net Sales by Business- MedSurg and Neurotechnology- Medical: $1.28 billion compared to the $1.3 billion average estimate based on five analysts. The reported number represents a change of +12.4% year over year.Net Sales by Business- MedSurg and Neurotechnology- Neuro Cranial: $669 million versus $704.73 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +11% change.Net Sales by Business- MedSurg and Neurotechnology- vascular: $539 million versus the five-analyst average estimate of $535.29 million. The reported number represents a year-over-year change of +58.1%.View all Key Company Metrics for Stryker here>>>Shares of Stryker have returned +1.8% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.SeeWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks